secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114437
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q3 revenue up 7% to $60.5M, cuts FY 2022 guidance to $232-$238M on macro headwinds
--------------------------------------------------------------------------------

- Q3 revenue $60.5M (+7% YoY); net loss $7.3M ($0.15/share); adj. EBITDA $4.7M vs $6.0M YoY.
- Full-year 2022 revenue guidance cut to $232-$238M, citing FX, COVID China, supply chain, Ukraine war headwinds.
- Supported 643 global clinical trials (+61 YoY); entered apheresis partnership with Takeda's BioLife.
- Cash $530M; repurchased 1.34M shares for $33.3M at avg $24.84; $100M program authorized through 2025.
- Gross margin 43.7% (+222 bps YoY); operating costs rose 22% to $34.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922114437/0001104659-22-114437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922114437/tm2229676d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer